Cargando…

Teriflunomide Concentrations in Cerebrospinal Fluid and Plasma in Patients with Multiple Sclerosis: A Pharmacokinetic Study

BACKGROUND: Teriflunomide is a disease modifying treatment (DMT) approved for relapsing-remitting multiple sclerosis (RRMS) in adults and children. It reduces lymphocyte proliferation by inhibiting the mitochondrial enzyme dihydroorotate dehydrogenase (DHODH) and thereby the pyrimidine synthesis. Al...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lycke, Jan, Farman, Helen, Nordin, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911485/ https://www.ncbi.nlm.nih.gov/pubmed/36729276 http://dx.doi.org/10.1007/s40263-023-00985-x

Ejemplares similares

Cerebrospinal fluid growth-associated protein 43 in multiple sclerosis
por: Sandelius, Åsa, et al.
Publicado: (2019)

Neuropathy in multiple sclerosis patients treated with teriflunomide
por: Kilic, Ahmet Kasim, et al.
Publicado: (2023)

An update of teriflunomide for treatment of multiple sclerosis
por: Oh, Jiwon, et al.
Publicado: (2013)

Teriflunomide in Patients with Relapsing–Remitting Forms of Multiple Sclerosis
por: Chan, Andrew, et al.
Publicado: (2016)

COVID-19 in teriflunomide-treated patients with multiple sclerosis
por: Maghzi, Amir Hadi, et al.
Publicado: (2020)

Vaccine Response in Patients With Multiple Sclerosis Receiving Teriflunomide
por: Tornatore, Carlo, et al.
Publicado: (2022)

Teriflunomide and Its Mechanism of Action in Multiple Sclerosis
por: Bar-Or, Amit, et al.
Publicado: (2014)

Role of oral teriflunomide in the management of multiple sclerosis
por: Tanasescu, Radu, et al.
Publicado: (2013)

Cerebrospinal fluid in multiple sclerosis
por: Rammohan, Kottil W.
Publicado: (2009)

The Cerebrospinal Fluid in Multiple Sclerosis
por: Deisenhammer, Florian, et al.
Publicado: (2019)

Review of teriflunomide and its potential in the treatment of multiple sclerosis
por: Warnke, Clemens, et al.
Publicado: (2009)

Teriflunomide Safety and Efficacy in Advanced Progressive Multiple Sclerosis
por: Moreira Ferreira, Vanessa F., et al.
Publicado: (2020)

Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis
por: Bar-Or, Amit, et al.
Publicado: (2013)

Teriflunomide for the treatment of relapsing–remitting multiple sclerosis: patient preference and adherence
por: Bayas, Antonios, et al.
Publicado: (2015)

Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis
por: Laplaud, David-Axel, et al.
Publicado: (2019)

Multiple Sclerosis Cerebrospinal Fluid Biomarkers
por: Giovannoni, Gavin
Publicado: (2006)

Serum Levels of CXCL13 Are Associated With Teriflunomide Response in Patients With Multiple Sclerosis
por: Fissolo, Nicolás, et al.
Publicado: (2022)

The impaired distribution of adenosine deaminase isoenzymes in multiple sclerosis plasma and cerebrospinal fluid
por: Kutryb-Zajac, Barbara, et al.
Publicado: (2022)

Integration of small RNAs from plasma and cerebrospinal fluid for classification of multiple sclerosis
por: Needhamsen, Maria, et al.
Publicado: (2022)

Safe Childbirth after Taking Teriflunomide in a Woman with Multiple Sclerosis
por: Cho, Bang-Hoon, et al.
Publicado: (2018)

Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis
por: Comi, Giancarlo, et al.
Publicado: (2020)

Teriflunomide treatment is associated with optic nerve recovery in early multiple sclerosis
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

Real-world discontinuation rate of teriflunomide and dimethyl fumarate in multiple sclerosis
por: Norborg, Hilde, et al.
Publicado: (2021)

Fibrinogen is not elevated in the cerebrospinal fluid of patients with multiple sclerosis
por: Ehling, Rainer, et al.
Publicado: (2011)

Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis
por: Callegari, Ilaria, et al.
Publicado: (2023)

Reducing return of disease activity in patients with relapsing multiple sclerosis transitioned from natalizumab to teriflunomide: 12-month interim results of teriflunomide therapy
por: Cohan, Stanley L, et al.
Publicado: (2019)

Cerebrospinal fluid mtDNA concentration is elevated in multiple sclerosis disease and responds to treatment
por: Leurs, Cyra E, et al.
Publicado: (2017)

Effect of nitazoxanide on albendazole pharmacokinetics in cerebrospinal fluid and plasma in rats
por: Ruiz-Olmedo, María Isabel, et al.
Publicado: (2017)

Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide
por: Bollo, Luca, et al.
Publicado: (2020)

Mild COVID‐19 infection in a group of teriflunomide‐treated patients with multiple sclerosis
por: Mantero, Vittorio, et al.
Publicado: (2020)

Hepatotoxicity associated with the use of teriflunomide in a patient with multiple sclerosis: A case report
por: Ferreira, Cristiane Munaretto, et al.
Publicado: (2021)

Medication Adherence and Healthcare Utilization in Relapsing-Remitting Multiple Sclerosis Patients Using Teriflunomide
por: Greene, Nupur, et al.
Publicado: (2022)

REMISSION OF HEREDITARY ANGIOEDEMA ATTACKS ASSOCIATED WITH STARTING TERIFLUNOMIDE IN A PATIENT WITH MULTIPLE SCLEROSIS
por: Fernández Romero, Diego S., et al.
Publicado: (2023)

A randomized trial of teriflunomide added to glatiramer acetate in relapsing multiple sclerosis
por: Freedman, MS, et al.
Publicado: (2015)

Teriflunomide Treatment of Multiple Sclerosis Selectively Modulates CD8 Memory T Cells
por: Tilly, Gaëlle, et al.
Publicado: (2021)

Teriflunomide in relapsing-remitting multiple sclerosis: outcomes by age and pre-treatment status
por: Kallmann, Boris A., et al.
Publicado: (2021)

Teriflunomide treatment outcomes in multiple sclerosis: A Portuguese real-life experience
por: Nunes, Carla Cecília, et al.
Publicado: (2023)

Natalizumab Induces Changes of Cerebrospinal Fluid Measures in Multiple Sclerosis
por: Ganapathy Subramanian, Ranjani, et al.
Publicado: (2021)

Quantitative proteomic analysis of the cerebrospinal fluid of patients with multiple sclerosis
por: Liu, Shilian, et al.
Publicado: (2009)

Oligoclonal Bands in Cerebrospinal Fluid of Black Patients with Multiple Sclerosis
por: da Gama, Paulo Diniz, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_gtrn6n71iqgkr4uppc80pjpluc